224 related articles for article (PubMed ID: 10553169)
1. Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
Randi ML; Fabris F; Girolami A
Haematologica; 1999 Nov; 84(11):1049-50. PubMed ID: 10553169
[No Abstract] [Full Text] [Related]
2. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Randi ML; Fabris F; Girolami A
Leuk Lymphoma; 2000 Apr; 37(3-4):379-85. PubMed ID: 10752989
[TBL] [Abstract][Full Text] [Related]
3. Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.
Sironi M; Bertola G; Lodato A; Spinelli M; Sciariada L
Acta Haematol; 2003; 109(3):161-2. PubMed ID: 12714827
[No Abstract] [Full Text] [Related]
4. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic transformation in a case of essential thrombocythemia treated with pipobroman.
Messora C; Bensi L; Vanzanelli P; Temperani P; Carotenuto M; Sacchi S
Haematologica; 1996; 81(1):51-3. PubMed ID: 8900853
[TBL] [Abstract][Full Text] [Related]
6. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.
Radaelli F; Onida F; Rossi FG; Zilioli VR; Colombi M; Usardi P; Calori R; Zanella A
Hematology; 2008 Aug; 13(4):195-202. PubMed ID: 18796244
[TBL] [Abstract][Full Text] [Related]
7. [Essential thrombocythemia: conventional therapy].
Grossi A; Vannucchi AM; Longo G; Rafanelli D; Rossi Ferrini P
Haematologica; 1991 Jun; 76 Suppl 3():368-70. PubMed ID: 1752534
[No Abstract] [Full Text] [Related]
8. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Nielsen I; Hasselbalch HC
Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
[TBL] [Abstract][Full Text] [Related]
9. Primary thrombocythemia.
Jamshidi K; Ansari A; Windschitl HE; Swaim WR
Geriatrics; 1973 Jan; 28(1):121-33. PubMed ID: 4539498
[No Abstract] [Full Text] [Related]
10. Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.
Passamonti F; Rumi E; Malabarba L; Arcaini L; Orlandi E; Brusamolino E; Pascutto C; Cazzola M; Lazzarino M
Ann Hematol; 2004 Aug; 83(8):495-7. PubMed ID: 15175894
[No Abstract] [Full Text] [Related]
11. Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea.
van den Anker-Lugtenburg PJ; Sizoo W
Am J Hematol; 1990 Feb; 33(2):152. PubMed ID: 2301374
[No Abstract] [Full Text] [Related]
12. [Essential thrombocythemia in transformation from myelodysplastic syndrome to acute myeloid leukemia with inv(3) after treatment for gastric cancer].
Horikoshi M; Machida U; Itikawa M; Seo S; Masuda S; Kurokawa M; Ogawa S; Sunaga S; Honda H; Aoki K; Chiba S; Mitani K; Hirai H; Yazaki Y
Rinsho Ketsueki; 2000 Jan; 41(1):68-71. PubMed ID: 10695403
[TBL] [Abstract][Full Text] [Related]
13. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients.
Chistolini A; Mazzucconi MG; Ferrari A; la Verde G; Ferrazza G; Dragoni F; Vitale A; Arcieri R; Mandelli F
Haematologica; 1990; 75(6):537-40. PubMed ID: 2098295
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Brusamolino E; Passamonti F; Volpe G; Pistorio A; Giardini I; Rocca B; Caresana M; Lazzarino M; Bernasconi C
Leukemia; 2002 Oct; 16(10):2078-83. PubMed ID: 12357360
[TBL] [Abstract][Full Text] [Related]
15. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.
Furgerson JL; Vukelja SJ; Baker WJ; O'Rourke TJ
Am J Hematol; 1996 Feb; 51(2):137-40. PubMed ID: 8579054
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.
Palandri F; Catani L; Testoni N; Ottaviani E; Polverelli N; Fiacchini M; De Vivo A; Salmi F; Lucchesi A; Baccarani M; Vianelli N
Am J Hematol; 2009 Apr; 84(4):215-20. PubMed ID: 19208420
[TBL] [Abstract][Full Text] [Related]
17. Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Najean Y; Rain JD; Dresch C; Goguel A; Lejeune F; Echard M; Grange MJ
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():111-9. PubMed ID: 8951781
[TBL] [Abstract][Full Text] [Related]
18. Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
Au WY; Chan LC; Liang R; Kwong YL
Am J Hematol; 2006 Jun; 81(6):471-3. PubMed ID: 16680740
[No Abstract] [Full Text] [Related]
19. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Björkholm M; Hultcrantz M; Derolf ÅR
Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
[TBL] [Abstract][Full Text] [Related]
20. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.
Finazzi G; Ruggeri M; Rodeghiero F; Barbui T
Br J Haematol; 2000 Sep; 110(3):577-83. PubMed ID: 10997967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
